Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429858 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Andrew Ko.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00429858 is a Phase 2 study that was terminated before completion, run by Andrew Ko. The registered enrollment target is 21 participants.
The verdict
NCT00429858, a Phase 2 study, was terminated before completion, sponsored by Andrew Ko.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial is studying gene expression in predicting treatment response in patients receiving gemcitabine and S-1 for locally advanced unresectable or metastatic pancreatic cancer.
Interventions
- DRUG S-1
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-01-22 |
| Est. Completion | 2010-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00429858
The ClinicalTrials.gov registry entry for NCT00429858 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrew Ko, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which S-1 is the first listed.
NCT00429858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00429858 about?
NCT00429858 is a clinical study titled "Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer". RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict a patient's response to treatment and help plan the best treat...
What is the current status of trial NCT00429858?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2007-01-22. Estimated completion is 2010-01-20.
What interventions are being tested in trial NCT00429858?
The interventions under investigation include: S-1 (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00429858?
This trial is sponsored by Andrew Ko, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.